Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo
Details
Publication Year 2017-05, Volume 24, Issue #5, Page 878-888
Journal Title
Cell Death and Differentiation
Publication Type
Journal Article
Abstract
Survival of various immune cell populations has been proposed to preferentially rely on a particular anti-apoptotic BCL-2 family member, for example, naive T cells require BCL-2, while regulatory T cells require MCL-1. Here we examined the survival requirements of multiple immune cell subsets in vitro and in vivo, using both genetic and pharmacological approaches. Our findings support a model in which survival is determined by quantitative participation of multiple anti-apoptotic proteins rather than by a single anti-apoptotic protein. This model provides both an insight into how the sum of relative levels of anti-apoptotic proteins BCL-2, MCL-1 and A1 influence survival of T cells, B cells and dendritic cells, and a framework for ascertaining how these different immune cells can be optimally targeted in treatment of immunopathology, transplantation rejection or hematological cancers.Cell Death and Differentiation advance online publication, 31 March 2017; doi:10.1038/cdd.2017.30.
Publisher
Springer Nature
WEHI Research Division(s)
Immunology; Cancer And Haematology; Molecular Genetics Of Cancer; Molecular Immunology
PubMed ID
28362427
Rights Notice
Refer to copyright notice on published article.


Creation Date: 2017-05-02 03:01:23
Last Modified: 2018-05-03 03:27:57
An error has occurred. This application may no longer respond until reloaded. Reload 🗙